Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma.

Bachet JB, Maréchal R, Demetter P, Bonnetain F, Couvelard A, Svrcek M, Bardier-Dupas A, Hammel P, Sauvanet A, Louvet C, Paye F, Rougier P, Penna C, Vaillant JC, André T, Closset J, Salmon I, Emile JF, Van Laethem JL.

Ann Oncol. 2012 Sep;23(9):2327-35. doi: 10.1093/annonc/mdr617. Epub 2012 Feb 29.

PMID:
22377565
2.

S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma.

Bachet JB, Maréchal R, Demetter P, Bonnetain F, Cros J, Svrcek M, Bardier-Dupas A, Hammel P, Sauvanet A, Louvet C, Paye F, Vaillant JC, André T, Closset J, Salmon I, Emile JF, Van Laethem JL.

Eur J Cancer. 2013 Aug;49(12):2643-53. doi: 10.1016/j.ejca.2013.04.017. Epub 2013 May 28.

PMID:
23726265
3.

Combined analysis of dihydropyrimidine dehydrogenase and human equilibrative nucleoside transporter 1 expression predicts survival of pancreatic carcinoma patients treated with adjuvant gemcitabine plus S-1 chemotherapy after surgical resection.

Kondo N, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Nakashima A, Sueda T.

Ann Surg Oncol. 2012 Jul;19 Suppl 3:S646-55. doi: 10.1245/s10434-011-2140-2. Epub 2011 Nov 16.

PMID:
22086444
4.

Failure patterns in resected pancreas adenocarcinoma: lack of predicted benefit to SMAD4 expression.

Winter JM, Tang LH, Klimstra DS, Liu W, Linkov I, Brennan MF, DʼAngelica MI, DeMatteo RP, Fong Y, Jarnagin WR, Oʼreilly EM, Allen PJ.

Ann Surg. 2013 Aug;258(2):331-5. doi: 10.1097/SLA.0b013e31827fe9ce.

5.

CXCR4--A Prognostic and Clinicopathological Biomarker for Pancreatic Ductal Adenocarcinoma: A Meta-Analysis.

Krieg A, Riemer JC, Telan LA, Gabbert HE, Knoefel WT.

PLoS One. 2015 Jun 19;10(6):e0130192. doi: 10.1371/journal.pone.0130192. eCollection 2015.

6.

The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer.

Riediger H, Keck T, Wellner U, zur Hausen A, Adam U, Hopt UT, Makowiec F.

J Gastrointest Surg. 2009 Jul;13(7):1337-44. doi: 10.1007/s11605-009-0919-2. Epub 2009 May 6.

PMID:
19418101
7.

SMAD4 expression predicts local spread and treatment failure in resected pancreatic cancer.

Yamada S, Fujii T, Shimoyama Y, Kanda M, Nakayama G, Sugimoto H, Koike M, Nomoto S, Fujiwara M, Nakao A, Kodera Y.

Pancreas. 2015 May;44(4):660-4. doi: 10.1097/MPA.0000000000000315.

PMID:
25760429
8.

Smad4 loss in esophageal adenocarcinoma is associated with an increased propensity for disease recurrence and poor survival.

Singhi AD, Foxwell TJ, Nason K, Cressman KL, McGrath KM, Sun W, Bahary N, Zeh HJ, Levy RM, Luketich JD, Davison JM.

Am J Surg Pathol. 2015 Apr;39(4):487-95. doi: 10.1097/PAS.0000000000000356.

9.

Phosphatase PPM1A is a novel prognostic marker in pancreatic ductal adenocarcinoma.

Fan J, Yang MX, Ouyang Q, Fu D, Xu Z, Liu X, Mino-Kenudson M, Geng J, Tang F.

Hum Pathol. 2016 Sep;55:151-8. doi: 10.1016/j.humpath.2016.05.002. Epub 2016 May 16.

PMID:
27195906
10.

A single institution review of adjuvant therapy outcomes for resectable pancreatic adenocarcinoma: outcome and prognostic indicators.

Kim R, Tsao R, Tan A, Byrne M, Almhanna K, Lazaryan A, Elson P, Pelley RJ.

J Gastrointest Surg. 2010 Jul;14(7):1159-69. doi: 10.1007/s11605-010-1213-z. Epub 2010 May 6.

PMID:
20446118
11.

Coexpression of EGFR and CXCR4 predicts poor prognosis in resected pancreatic ductal adenocarcinoma.

Wu H, Zhu L, Zhang H, Shi X, Zhang L, Wang W, Xue H, Liang Z.

PLoS One. 2015 Feb 13;10(2):e0116803. doi: 10.1371/journal.pone.0116803. eCollection 2015.

12.

Clinical outcome and expression of mutant P53, P16, and Smad4 in lung adenocarcinoma: a prospective study.

Bian C, Li Z, Xu Y, Wang J, Xu L, Shen H.

World J Surg Oncol. 2015 Mar 28;13:128. doi: 10.1186/s12957-015-0502-0.

13.

Ribonucleotide reductase M2 does not predict survival in patients with resectable pancreatic adenocarcinoma.

Xie H, Lin J, Thomas DG, Jiang W, Liu X.

Int J Clin Exp Pathol. 2012;5(4):347-55. Epub 2012 Apr 16.

14.

Prognostic factors and adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.

You DD, Lee HG, Heo JS, Choi SH, Choi DW.

J Gastrointest Surg. 2009 Sep;13(9):1699-706. doi: 10.1007/s11605-009-0969-5. Epub 2009 Jul 7.

PMID:
19582512
15.

Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy for resected pancreatic cancer.

Hall WA, Petrova AV, Colbert LE, Hardy CW, Fisher SB, Saka B, Shelton JW, Warren MD, Pantazides BG, Gandhi K, Kowalski J, Kooby DA, El-Rayes BF, Staley CA 3rd, Volkan Adsay N, Curran WJ, Landry JC, Maithel SK, Yu DS.

Oncogene. 2014 Nov 20;33(47):5450-6. doi: 10.1038/onc.2013.488. Epub 2013 Nov 25.

PMID:
24276239
16.

DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer.

Drouillard A, Puleo F, Bachet JB, Ouazzani S, Calomme A, Demetter P, Verset G, Van Laethem JL, Maréchal R.

Br J Cancer. 2016 Nov 8;115(10):1245-1252. doi: 10.1038/bjc.2016.319. Epub 2016 Oct 18.

PMID:
27755532
17.

Pronecrotic mixed lineage kinase domain-like protein expression is a prognostic biomarker in patients with early-stage resected pancreatic adenocarcinoma.

Colbert LE, Fisher SB, Hardy CW, Hall WA, Saka B, Shelton JW, Petrova AV, Warren MD, Pantazides BG, Gandhi K, Kowalski J, Kooby DA, El-Rayes BF, Staley CA 3rd, Adsay NV, Curran WJ Jr, Landry JC, Maithel SK, Yu DS.

Cancer. 2013 Sep 1;119(17):3148-55. doi: 10.1002/cncr.28144. Epub 2013 May 29.

18.

Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.

Oshima M, Okano K, Muraki S, Haba R, Maeba T, Suzuki Y, Yachida S.

Ann Surg. 2013 Aug;258(2):336-46. doi: 10.1097/SLA.0b013e3182827a65.

PMID:
23470568
19.

Addition of radiotherapy to adjuvant chemotherapy is associated with improved overall survival in resected pancreatic adenocarcinoma: An analysis of the National Cancer Data Base.

Rutter CE, Park HS, Corso CD, Lester-Coll NH, Mancini BR, Yeboa DN, Johung KL.

Cancer. 2015 Dec 1;121(23):4141-9. doi: 10.1002/cncr.29652. Epub 2015 Aug 17.

20.

Towards a tailored therapy in pancreatic cancer.

Maréchal R, Van Laethem JL.

Acta Gastroenterol Belg. 2013 Mar;76(1):49-56.

PMID:
23650783

Supplemental Content

Support Center